Search research articles
Contact Us
Filters
Showing results (21-30 of 26) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 26 results.
The New Zealand Medical Journal
|
August 25, 2004
Management of patients admitted with an Acute Coronary Syndrome in New Zealand: results of a comprehensive nationwide audit
Chris Ellis, Greg Gamble, John French, et al.
The New Zealand Medical Journal
|
August 25, 2004
Acute Coronary Syndrome patients in New Zealand receive less invasive management when admitted to hospitals without invasive facilities
Chris Ellis, Gerald Devlin, Philip Matsis, et al.
American Heart Journal
|
March 20, 2012
Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Andrew Tonkin, David Hunt, Merryn Voysey, et al.
Heart, Lung & Circulation
|
November 19, 2017
All-Cause Mortality Following an Acute Coronary Syndrome: 12-Year Follow-Up of the Comprehensive 2002 New Zealand Acute Coronary Syndrome Audit
Chris J Ellis, Greg D Gamble, Michael J A Williams, et al.
European Heart Journal
|
October 3, 2009
Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
David C Burgess, David Hunt, Liping Li, et al.
The New Zealand Medical Journal
|
April 7, 2017
A decade of improvement in the management of New Zealand ST-elevation myocardial infarction (STEMI) patients: results from the New Zealand Acute Coronary Syndrome (ACS) Audit Group national audits of 2002, 2007 and 2012
John M Elliott, Tom Kai Ming Wang, Greg D Gamble, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 26) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 26 results.
The New Zealand Medical Journal
|
August 25, 2004
Management of patients admitted with an Acute Coronary Syndrome in New Zealand: results of a comprehensive nationwide audit
Chris Ellis, Greg Gamble, John French, et al.
The New Zealand Medical Journal
|
August 25, 2004
Acute Coronary Syndrome patients in New Zealand receive less invasive management when admitted to hospitals without invasive facilities
Chris Ellis, Gerald Devlin, Philip Matsis, et al.
American Heart Journal
|
March 20, 2012
Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
Andrew Tonkin, David Hunt, Merryn Voysey, et al.
Heart, Lung & Circulation
|
November 19, 2017
All-Cause Mortality Following an Acute Coronary Syndrome: 12-Year Follow-Up of the Comprehensive 2002 New Zealand Acute Coronary Syndrome Audit
Chris J Ellis, Greg D Gamble, Michael J A Williams, et al.
European Heart Journal
|
October 3, 2009
Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
David C Burgess, David Hunt, Liping Li, et al.
The New Zealand Medical Journal
|
April 7, 2017
A decade of improvement in the management of New Zealand ST-elevation myocardial infarction (STEMI) patients: results from the New Zealand Acute Coronary Syndrome (ACS) Audit Group national audits of 2002, 2007 and 2012
John M Elliott, Tom Kai Ming Wang, Greg D Gamble, et al.
Page
of 3